FRCPath Haem Part 1 MCQ-Oncology 27

According to 2025 BSH guideline for R/R LBCL, which of following is preferred 2nd-line option for transplant-eligible patients relapsing in 12M of RCHOP?

• DHAP followed by autologous SCT
• R-ICE followed by autologous SCT
• CAR-T cell therapy
• Lenalidomide monotherapy

See All Options